ND40066-clone 7, ND40066-PINK1/PARK6-ILE368ASN-clone 7

General

Cell Line

hPSCreg name LCSBi002-B
Cite as:
LCSBi002-B (RRID:CVCL_A8LU)
Alternative name(s)
ND40066-clone 7, ND40066-PINK1/PARK6-ILE368ASN-clone 7
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
LCSBi002-C
(ND40066-clone 8, ND40066-PINK1/PARK6-ILE368ASN-clone 8)
Donor's gene variants:
PINK1, PINK1
Donor diseases:
Parkinson Disease
ICGi042-A
(PD12-4Lm)
Donor's gene variants:
LRRK2, PINK1
Donor diseases:
Parkinson Disease
ICGi042-B
(PD12-5Lm)
Donor's gene variants:
LRRK2, PINK1
Donor diseases:
Parkinson Disease
ICGi042-C
(PD12-6Lm)
Donor's gene variants:
LRRK2, PINK1
Donor diseases:
Parkinson Disease
DANi007-A
(PINK1-007-C1)
Donor's gene variants:
PINK1
Donor diseases:
Parkinson Disease
GIBHi003-A
(PINK1-I368N-C2)
Donor's gene variants:
PINK1
Donor diseases:
Parkinson Disease
SUSMi005-A-4
(SNCA3X 3KO C1, SNCA3X 3KO C2)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-5
(SNCA3X 4KO C1, SNCA3X 4KO C2)
Donor diseases:
obsolete_Parkinson's disease
LCSBi011-A-1
(RHOT1_T351A_clone25.2_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi012-A-1
(RHOT1_T610A_clone62.19.37_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi008-A-1
(delP GC13, DJ-1-delP GC13)
Donor diseases:
Parkinson Disease
SUSMi005-A-1
(SNCA3X 0KO C1, SNCA3X 0KO C2)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-2
(SNCA3X 1KO C2, SNCA3X 1KO C1)
Donor diseases:
obsolete_Parkinson's disease
SUSMi005-A-3
(SNCA3X 2KO C1, SNCA3X 2KO C2)
Donor diseases:
obsolete_Parkinson's disease
EDi001-A-1
(AST22-C, AST23-C)
Donor's gene variants:
SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-2
(AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-3
(AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-4
(AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
MPIi003-A-1
(IM2GC, L2-2GC)
Donor diseases:
obsolete_Parkinson's disease
EDi001-B-1
(AST18-7A)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-2
(AST18-7B)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-3
(AST18-5D)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-B-4
(AST18-6A)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi001-A-5
(AST23-2KO-II8B)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi004-B-1
(SFC832-03-06 LRRK2WT/WT C47)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
LCSBi009-A-1
(RHOT1_R272Q_clone18_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi010-A-1
(RHOT1_R450C_clone6_IsogenicControl)
Donor diseases:
Parkinson Disease
LCSBi010-A-2
(RHOT1_R450C_clone10_IsogenicControl)
Donor diseases:
Parkinson Disease
ICGi015-B-1
(m6.7pCyto-17)
Donor diseases:
Parkinson Disease
ICGi015-B-2
(m6.7pCyto-21)
Donor diseases:
Parkinson Disease
ICGi015-B-3
(m6.7pCyto-24)
Donor diseases:
Parkinson Disease
ICGi034-A-1
(PD30-XBP-RFP-6, PD30-4-7-XBP-RFP-6)
Donor diseases:
obsolete_Parkinson's disease
ICGi034-A-2
(PD30-4-7-XBP-RFP-51, PD30-XBP-RFP-51)
Donor diseases:
obsolete_Parkinson's disease
STBCi090-B
(SFC867-04-12)
Donor diseases:
Parkinson disease
PNUSCRi001-A
(GBA PD iPSC7)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
LCSBi008-A
(delP, DJ-1-delP)
Donor diseases:
Parkinson Disease
PNUSCRi002-A
(GBA PD iPSC9)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
STBCi005-B
(SFC833-03-05)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi005-C
(SFC833-03-14)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi007-B
(SFC855-03-08)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi007-C
(SFC855-03-01)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
LCSBi001-A
(VPS35 1_2)
Donor diseases:
obsolete_Parkinson's disease
LCSBi013-A
(GL2)
Donor diseases:
Parkinson Disease
CDIi013-A
(PPMI_3409, FCDI_11287)
Donor diseases:
Parkinson Disease
CDIi014-A
(FCDI_11292, PPMI_4055)
Donor diseases:
Parkinson Disease
CDIi017-A
(PPMI_3446, FCDI_11296)
Donor diseases:
Parkinson Disease
CDIi018-A
(PPMI_3234, FCDI_11298)
Donor diseases:
Parkinson Disease
CDIi019-A
(PPMI_52062, FCDI_11299)
Donor diseases:
Parkinson Disease
CDIi021-A
(PPMI_3459, FCDI_11301)
Donor diseases:
Parkinson Disease
CDIi023-A
(FCDI_11303, PPMI_3448)
Donor diseases:
Parkinson Disease
Last update 25th January 2023
Notes Stem Cell Research: Generation of two human induced pluripotent stem cell lines from fibroblasts of Parkinson’s disease patients carrying the ILE368ASN mutation in PINK1 (LCSBi002) and the R275W mutation in Parkin (LCSBi004).
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Luxembourg Centre for Systems Biomedicine (LCSB)
Owner Luxembourg Centre for Systems Biomedicine (LCSB)
Distributors
Derivation country United States

External Databases

Cellosaurus CVCL_A8LU
Wikidata Q108820768
BioSamples SAMEA13093853

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 60-64
Ethnicity Caucasian, Poland

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
young onset (at 33 years of age)
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Parkinson Disease
  • Parkinson's disease
  • Parkinson's Disease
Genetic variants
PINK1 (target)
chr1:20645703 (GRCh38.p13)
NM_032409.3:c.1103T>A
NP_115785.1:p.Ile368Asn
Homozygous
PMID: 35027645
Stem Cell Research: Generation of two human induced pluripotent stem cell lines from fibroblasts of Parkinson’s disease patients carrying the ILE368ASN mutation in PINK1 (LCSBi002) and the R275W mutation in Parkin (LCSBi004).
Disease associated phenotypes
  • dysautonomia
  • Fluctuations in attention or alertness
  • Asymmetric onset
  • Bradykinesis
  • Gait difficulties
  • Anti-Parkinsonism Therapy tried and responsive
  • Resting Tremor
  • Rigidity
Non-disease associated phenotypes
  • current smoker, smoked for 15 years
Family history 1 brother and one sister affected by Parkinson's disease, family NINDS5499
Is clinical information available? on Coriell Institute website

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46,XY[20] ApparentlyNORMALHumanMaleKaryotype
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA13093854

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. Coriell Institute Link to general submission information: https://www.coriell.org/1/NINDS/About/How-to-Submit Consent forms are maintained by the submitting sites, and each submitting site has its own consent form, but they must be approved by the NINDS. You can find more information about the terms under which subjects are consented here: https://catalog.coriell.org/1/NINDS/About/NINDS-Repository-FAQ
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information Consent forms are maintained by the submitting sites, and each submitting site has its own consent form, but they must be approved by the NINDS. You can find more information about the terms under which subjects are consented here: https://catalog.coriell.org/1/NINDS/About/NINDS-Repository-FAQ
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? Yes
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website: available on Coriell Institute website https://www.coriell.org/Search?q=ND40066&grid=1
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Samples were collected in accordance with the US Government guidelines and are subject to MTA issued by Coriell Institute for Medical Research NINDS Cell Repository. The iPSC reprogramming protocol was approved by the Committee on Human Research at the University of California, San Francisco.
Approval number
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Samples were collected in accordance with the US Government guidelines and are subject to MTA issued by Coriell Institute for Medical Research NINDS Cell Repository. The iPSC reprogramming protocol was approved by the Committee on Human Research at the University of California, San Francisco.
Approval number
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? CytoTune-iPS Sendai Reprogramming kit (ThermoFisher Scientific).
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell line name ND40066
Source cell type
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms
Source cell origin
Source cell line lot number
LCSBi002-A, LCSBi002-C
Age of donor (at collection) 60-64
Source cell line vendor Coriell
Passage number reprogrammed 2

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR
Notes on reprogramming vector detection via Scorecard
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Other

Selection criteria for clones Oct3/4 and Tra-1-60 ICC, morphology
Derived under xeno-free conditions
Yes
Derived under GMP?
Yes
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
Accutase
CO2 Concentration 5 %
Medium mTeSR™ 1
Supplements
MTeSR1 supplement 1x %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
SOX2
Yes
NANOG
Yes
Morphology pictures
Self-renewal
Positive
Endoderm
Negative
Mesoderm
Negative
Ectoderm score
Negative
Data analysis report
Transcriptome Characterisation
Differentiation Potency
Ectoderm
Ont Id: UBERON_0000924
Scorecard
Protocol or reference

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Not done
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Normal human male
Passage number: 9
Karyotyping method: Array CGH

Other Genotyping (Cell Line)